Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

VitaNova Life Sciences (YJGJ) Cash from Financing Activities (2017 - 2025)

VitaNova Life Sciences (YJGJ) has disclosed Cash from Financing Activities for 8 consecutive years, with -$101500.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Cash from Financing Activities fell 320.55% year-over-year to -$101500.0, compared with a TTM value of -$128000.0 through Oct 2025, down 112.08%, and an annual FY2025 reading of -$3000.0, down 100.31% over the prior year.
  • Cash from Financing Activities was -$101500.0 for Q2 2025 at VitaNova Life Sciences, down from -$26500.0 in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $958913.0 in Q1 2024 and bottomed at -$101500.0 in Q2 2025.
  • Average Cash from Financing Activities over 4 years is $82662.1, with a median of $9853.0 recorded in 2021.
  • The sharpest move saw Cash from Financing Activities skyrocketed 23872.82% in 2024, then tumbled 320.55% in 2025.
  • Year by year, Cash from Financing Activities stood at $12100.0 in 2021, then plummeted by 33.96% to $7991.0 in 2023, then skyrocketed by 806.02% to $72400.0 in 2024, then tumbled by 240.19% to -$101500.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for YJGJ at -$101500.0 in Q2 2025, -$26500.0 in Q1 2025, and $72400.0 in Q4 2024.